B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Chronic lymphocytic leukemia (CLL) is a malignancy of mature, antigen-experienced B
lymphocytes. Despite great progress recently achieved in the management of CLL, the …

Cancer treatment has been transformed by checkpoint blockade therapies, with the highest
anti-tumor activity of anti-programmed death 1 (PD-1) antibody therapy seen in Hodgkin …

The Bruton tyrosine kinase inhibitor ibrutinib induces high rates of clinical response in
chronic lymphocytic leukemia (CLL). However, there remains a need for adjunct treatments …

Patients with chronic lymphocytic leukemia can be divided into three categories: those who
are minimally affected by the problem, often never requiring therapy; those that initially …

Chronic lymphocytic leukemia (CLL) is associated with substantial alterations in T-cell
composition and function. However, the role of T-cells in CLL remains largely controversial …

Bruton tyrosine kinase (BTK) is essential for B-cell receptor (BCR) signaling, a driver of
chronic lymphocytic leukemia (CLL). Covalent inhibitors bind C481 in the active site of BTK …

Cancer pathogenesis involves the interplay of tumor-and microenvironment-derived stimuli.
Here we focused on the influence of an immunomodulatory cell type, myeloid-derived …

Follicular helper T cells (TFH) have specialized properties in promoting normal B cell
activation but their role in chronic lymphocytic leukemia (CLL) is unknown. We find that TFH …

Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of small
mature-looking CD19+ CD23+ CD5+ B-cells that accumulate in the blood, bone marrow …